Incyte (NAS:INCY) Momentum Rank

: 10 (As of Today)

View and export this data going back to 1993. Start your Free Trial

Incyte has the Momentum Rank of 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison

For the Biotechnology subindustry, Incyte's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Incyte Momentum Rank Distribution

For the Biotechnology industry and Healthcare sector, Incyte's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Incyte's Momentum Rank falls in comparison to its industry or sector. The grey bar indicates the Momentum Rank's extreme value range as defined by GuruFocus.

Incyte Momentum Rank Related Terms

Thank you for viewing the detailed overview of Incyte's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Incyte (NAS:INCY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (NAS:INCY) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

INCY:Mexico 0J9P:UK ICY:Germany ICY:Germany I1NC34:Brazil INCY:Austria

Address

1801 Augustine Cut-Off, Wilmington, DE, USA, 19803

Website

https://www.incyte.com

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Executives

Tray Thomas	officer: Principal Accounting Officer	C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Brawley Otis W	director	5203 BRISTOL INDUSTRIAL WAY BUFORD GA 30518
High Katherine A	director	3737 MARKET STREET SUITE 1300 PHILADELPHIA PA 19104
Harrigan Edmund	director
Morrissey Michael James	officer: EVP, Head of Tech. Operations	IN CARE OF INCYTE CORPORATION 1801 AUGUSTINE CUT OFF WILMINGTON DE 19803
Dickinson Jonathan Elliott	officer: EVP, General Manager, Europe	CARE OF INCYTE CORPORATION 1801 AUGUSTINE CUT OFF WILMINGTON DE 19803
Stamoulis Christiana	officer: EVP & Chief Financial Officer	C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST CAMBRIDGE MA 02139
Dhanak Dashyant	officer: EVP & Chief Scientific Officer	C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Pasquale Maria E	officer: EVP & General Counsel	C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Fouse Jacqualyn A	director	C/O DICK'S SPORTING GOODS 345 COURT STREET CORAOPOLIS PA 15108
Iyengar Vijay K	officer: EVP GPS, BD, & Licensing	1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Stein Steven H	officer: EVP & Chief Medical Officer	1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Trower Paul	officer: VP, Finance & Prin Acc Officer	1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Clancy Paul J	director	C/O BIOGEN IDEC INC. 14 CAMBRIDGE CENTER CAMBRIDGE MA 02142
Bienaime Jean Jacques	director	925 PAGE MILL ROAD PALO ALTO CA 94304